Diorasis Therapeutics is an ophthalmic early-stage company focusing on first-in-class disease-modifying gene-agnostic gene therapy for normalizing outflow facility in the trabecular meshwork and decreasing IOP in open angle glaucoma patients. We have multiple publications in leading ophthalmology and gene therapy journals of in vitro and in vivo experiments supporting the mechanism of action and demonstrating strong efficacy and preliminary safety in multiple small and large animals:

• lowering IOP in steroid-induced glaucoma in mice
• lowering IOP in myocilin genetic glaucoma model in mice
• lowering IOP in steroid-induced glaucoma model in sheep
• not-lowering IOP in normal mice (avoiding risk of hypotony)

Currently we are working on IND-enabling safety and toxicology experiments. Our goal is to transform the lives of millions of patients with glaucoma suffering from partial visual loss and minimize their risk of becoming completely blind. Diorasis in Greek means the power to perceive things in the future and the ability to see things that others cannot.